MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 TrialA. Jo Chien, Laura J. Esserman, Debasish Tripathy et al.|Journal of Clinical Oncology|2020Cited by 113
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E. Lang, Laura J. Esserman, Andres Forero‐Torres et al.|npj Breast Cancer|2022Cited by 27
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036Steven P. Angus, Gary L. Johnson, Timothy J. Stuhlmiller et al.|npj Breast Cancer|2021Cited by 24
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast CancerMohamed A. Gouda, Funda Meric‐Bernstam, Rashmi K. Murthy et al.|Clinical Cancer Research|2025Cited by 13